Tumor necrosis factor-α inhibitors (TNFis) have transformed care for rheumatoid arthritis and other autoimmune diseases, but they also are associated with higher risks of serious and opportunistic infections than traditional disease-modifying antirheumatic drugs. In this article, Cassandra Calabrese, DO, discusses balancing the benefits of biologic therapies with the risks of infection.
Clinicians do not administer reactive TDM or objective disease activity assessments prior to making changes in biologic therapies in almost a third of patients with IBD.
After two decades of using biologics for IMIDs, we now have an armamentarium, including five drugs and a number of biosimilars, that continues to grow at a record pace.
Whether you plan to complete the entire series or prefer to pick a handful of individual webcasts most relevant to your practice, don’t miss this complimentary educational opportunity.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Denosumab and romosozumab work on different pathways but offer new options for patients with low bone mass as primary therapy and for those unresponsive to or contraindicated for bisphosphonates.
Individuals with clinically unapparent HBV and concomitant immune-mediated inflammatory diseases (IMIDs) (e.g., rheumatoid arthritis, psoriasis, inflammatory bowel disease and others) are particularly vulnerable to HBV reactivation when immunosuppressed.
Primary Vasculitides: Best Practices and Future Advances, a one day symposium on April 5, 2017, will explore Giant Cell Arteritis and other forms of vasculitis.
When this CME summit was last offered two years ago, it drew hundreds of attendees from over 30 states and nine countries. Even more are expected this time. Here’s why you should be among them.